Tamoxifen citrate suppliers

Tamoxifen citrate

CAS:: 54965-24-1

MF:: C32H37NO8

MW:: 563.64

SecurityInformation

Symbol(GHS) ：: GHS07,GHS08,GHS09

Signal word ：: Danger

Hazard statements ：: H302-H350-H360D-H410

Precautionary statements ：: P201-P202-P264-P273-P301+P312-P308+P313

Hazard Codes ：: T,Xi

Risk Statements ：: 45-60-61-22-64-36/37/38

Safety Statements ：: 53-36/37/39-45-36-26

RIDADR ：: UN 3077 9 / PGIII

WGK Germany ：: 3

RTECS ：: KH2387000

HazardClass ：: IRRITANT

HS Code ：: 29225090

Toxicity：: LD50 in mice, rats (mg/kg): 200, 600 i.p.; 62.5, 62.5 i.v.; 3000-6000, 1200-2500 orally (Furr, Jordan)

Use：: Tamoxifen Citrate is a selective estrogen response modifier (SERM), protein kinase C inhibitor and anti-angiogenetic factor. Tamoxifen is a prodrug that is metabolized to active metabolites 4-hydroxytamoxifen (4-OHT) and endoxifen by cytochrome P450 isoforms CYP2D6 and CYP3A4. Tamoxifen is used for the treatment of invasive breast cancer in men and women, the most common type of breast cancer, following surgery and/or radiation and for preventing invasive breast cancer in women at high risk for developing it. Tamoxifen also is used for the treatment of women following surgery and radiation for a less common type of breast cancer called ductal carcinoma in situ (DCIS or Intraductal Carcinoma). Women who have had DCIS are at high risk for developing invasive breast cancer at a later date, and tamoxifen prevents development of the invasive cancer in almost half of the women during the first five years of treatment.

More▼

You can find Tamoxifen citrate suppliers, manufacturers, and distributors from countries such as China, United States and the United Kingdom here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.

Guangzhou TongYi biochemistry technology Co.,LTD